XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
New study presents a human-relevant stress model for assessing potential therapeutics
Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ
Prolia is a prescription medicine used to treat osteoporosis in women
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Encouraging early detection and breaking the silence around men’s health
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Cagrilintide represents a novel approach to obesity management
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Subscribe To Our Newsletter & Stay Updated
